The Discounted Cash Flow (DCF) valuation of Theravance Biopharma Inc (TBPH) is (16.36) USD. With the latest stock price at 13.87 USD, the upside of Theravance Biopharma Inc based on DCF is -217.9%.
Based on the latest price of 13.87 USD and our DCF valuation, Theravance Biopharma Inc (TBPH) is a sell. selling TBPH stocks now will result in a potential gain of 217.9%.
Note: valuation result may not be accurate due to the company's negative cashflows.
| Range | Selected | |
| WACC / Discount Rate | 6.3% - 9.8% | 8.0% |
| Long-term Growth Rate | 3.0% - 5.0% | 4.0% |
| Fair Price | (60.64) - (7.85) | (16.36) |
| Upside | -537.2% - -156.6% | -217.9% |